Cardiology · 3 h ago
IRONMAN analysis estimates NHS savings with ferric derisomaltose for heart failure
A cost-utility analysis using individual patient data from IRONMAN estimated that intravenous ferric derisomaltose saved £580 per patient over one year compared with usual care. From the NHS England perspective, reduced hospitalisation and end-of-life care costs offset treatment costs in patients with heart failure and iron deficiency.
- Analysis used individual patient-level data from the IRONMAN trial.
- Estimated one-year savings were £580 per patient.
- Hospitalisation savings offset ferric derisomaltose acquisition and administration costs.
- Longer-term cost-effectiveness was not established.
A health economic analysis published in ESC Heart Failure assessed intravenous ferric derisomaltose versus usual care using individual patient-level data from the IRONMAN trial. The trial enrolled patients with new or established heart failure, iron deficiency and left ventricular ejection fraction ≤45%. The cost-utility model adopted an NHS England perspective over one year, incorporating participant-completed EQ-5D-5L quality-of-life questionnaires, all non-elective hospitalisations and end-of-life care. The abstract did not report sample size.
Estimated quality-adjusted life years were 0.563 with ferric derisomaltose versus 0.547 with usual care, a difference of 0.016 (95% credible interval, 0.002–0.032). Incremental acquisition and administration costs of £357 were offset by £936 in savings from avoided hospitalisations and end-of-life care. Net savings were £580 per patient (95% credible interval, £493–£678), approximately 15% below usual-care costs.
The findings suggest potential short-term NHS savings, driven primarily by reduced hospitalisation rates. However, this is a within-trial economic analysis rather than a new clinical efficacy trial, and its one-year horizon does not establish longer-term cost-effectiveness. Full text was unavailable, limiting assessment of model assumptions, sensitivity analyses and funding disclosures.
Is this summary clinically accurate?
Help fellow clinicians: your rating sends inaccurate summaries straight to our editors.
Sign in to rate this summary →Source
ESC Heart Failure: Cost-effectiveness of intravenous ferric derisomaltose for patients with heart failure and iron deficiency in the UK based on the IRONMAN trial results ↗This is an automated AI-condensed summary that has not yet been reviewed by an editor. Always consult the full item at the original source.